On February 20, 2019 Sapreme Technologies, a privately-held biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics, has been awarded a 6.8 M€ grant together with a multidisciplinary consortium including 11 other academic and industrial parties (Press release, Sapreme Technologies, FEB 20, 2019, View Source [SID1234538877]). The grant was provided by the European Union (EU) through Horizon 2020 to develop a non-viral based gene therapy using Sapreme’s proprietary endosomal escape enhancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ruben Postel, CSO of Sapreme Technologies, "We are pleased to see that the EU has recognized the great potential of the ENDOSCAPE project and the expert multi-disciplinary consortium developing a novel oligonucleotide delivery technology for treatment of cancer and haemophilia patients"

Ernst Geutjes, acting Managing Director, "The fact that the EU awarded the proposal with the maximum score demonstrates the potential of Sapreme’s proprietary endosomal escape enhancement technology as well as the exceptional quality of the proposal and the consortium spearheaded by Sapreme and Charité – Universitätsmedizin Berlin"

On February 20, 2019 THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specialiazing in in vitro diagnostics and theranostics, reported its consolidated full-year revenues for 2018 and its cash position at December 31, 2018, figures which are currently being audited (Press release, Theradiag, FEB 20, 2019, View Source;utm_medium=rss&utm_campaign=theradiag-reports-annual-revenues-for-2018-and-its-year-end-cash-position [SID1234533518]).

In the year to December 31, 2018, Theradiag generated consolidated revenues of €8.9 million, from €9.0 million in 2017. Activity over the year was affected by the drop in theranostics revenues, which did not see exceptional orders in the first half of the year, whereas in the first half of 2017 revenues were boosted by strong activity levels following the signature of agreements with pharmaceutical companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thus 96% of theranostics revenues was generated by the sale of kits for routine use, which grew by 17% relative to 2017. Export sales of theranostic kits for routine use grew by 19%.

Revenues from IVD were stable, rising 1%.

"Despite the absence of non-recurrent sales in 2018, overall revenues were stable and the sales of LISA TRACKER kits for routine use continued to rise both in France and in export markets, with total growth of 17%. This reflects continued market penetration and the growing use of routine monitoring of patients, driven in particular by the development of biotherapies for chronic conditions. Over the year, Theradiag is likely to maintain the trends established and approach breakeven." commented Bertrand de Castelnau, CEO of Theradiag.

Cash position

At December 31, 2018 the Group had net cash of €3.4 million, compared to €5.2 million a year earlier.

Next press Release:

Full year earnings 2018: March 27, 2019

This date is given for indicative purposes and may be changed.

On February 20, 2019 Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019, at 1:00 p.m. EST at the Lotte New York Palace Hotel (Press release, Heron Therapeutics, FEB 20, 2019, View Source [SID1234533544]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this presentation will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

On February 20, 2019 Alkermes plc (Nasdaq: ALKS) reported that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 27, 2019 at 2:30 p.m. ET (7:30 p.m. BST) from New York, NY (Press release, Alkermes, FEB 20, 2019, View Source;p=irol-newsArticle&ID=2388210 [SID1234533543]). The audio portion of the fireside chat may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

On February 20, 2019 Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, reported it will report its fourth quarter and full year 2018 financial results and business progress on Wednesday, February 27, 2019, after the close of the U.S. financial markets (Press release, Tocagen, FEB 20, 2019, View Source;p=RssLanding&cat=news&id=2388299 [SID1234533540]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, Marty Duvall, chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, at 9:30 a.m. ET in New York City.

The live audio webcast from the conference and subsequent replay may be accessed by visiting Tocagen’s website. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 90 days following the presentation.

To receive Tocagen’s press releases and other investor information, please visit the Investor Relations page of the company’s website and register for email alerts.